Melinda Taschetta-Millane, Editorial Director
Blog | Melinda Taschetta-Millane, Editorial Director | Women's Health| May 05, 2017

Projected ABUS Growth

ABUS, women's health

Image courtesy of GE Healthcare

Although new technology and research has helped in the fight against breast cancer, death rates continue to be steady in women younger than 50, and continue to decrease in older women, according to the American Cancer Society (ACS). This decline is believed to be a result of finding breast cancer earlier thanks to improved screening technology, better treatment options and widespread awareness.  

The ACS estimates that about 252,710 new cases of invasive breast cancer will be diagnosed, and about 63,410 new cases of carcinoma in situ (CIS) will be diagnosed in women in 2017. More than 40,000 women will die from this disease this year alone.

The introduction of advanced technologies has made it possible to detect small cancer tumors as well as improve dense breast tissue scanning, and much of this technology has gained popularity due to its non-invasive, radiation-free and 3-D imaging features for breast cancer diagnosis. According to a new research report by Global Market Insights, Inc., this will help drive automated breast ultrasound system (ABUS) market growth.

Like traditional ultrasound, ABUS uses high-frequency sound waves targeted at the breast, but the scans provide physicians with a 3-D volumetric image of the entire breast. These 3-D images are more beneficial to women within the dense breast population because they allow radiologists the ability to check the breast from a variety of angles and offer a better interpretation. ABUS exams are also much shorter than traditional ultrasound, with some systems taking as little as seven minutes to perform a bilateral exam — less than half the time of some traditional ultrasounds. Because the transducer used in ABUS automatically scans the breast, the operator dependency is greatly reduced.

According to the report, increasing product innovation for development of more advanced breast cancer detection techniques will propel ABUS market growth, along with the fairly recent technological advancement of automated breast volume scanners (ABVS). The report states that the ABVS market is slated to exceed USD 950 million by 2024, growing at more than a 20 percent compound annual growth rate (CAGR). Some of the benefits of ABVS include high reproducibility of images, reduced scan time and delivery of coronal view 3-D images with high sensitivity. It also provides high resolution imaging with innovative applications such as fatty tissue imaging and elasticity imaging. 

New technologies are being introduced by some of the industry’s key players. You can learn more about the growth of the ABUS market in this month’s feature, “ABUS Driving Personalized Breast Cancer Screening,” which can be found here.

You can also view the video “Innovative Breast Cancer Screening for Women with Dense Breast Tissue,” in which Monica Saini, M.D., consultant medical director — ABUS at GE Healthcare, discusses the necessity for personalized breast care, and how ABUS helps meet the challenges of screening and diagnostic imaging of dense breast tissue. You can find the video at http://bit.ly/2q2On0c.

Related Content

Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
International Trial Confirms Safety, Effectiveness of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer
News | Brachytherapy Systems, Women's Healthcare | October 04, 2017
Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy or...
Kubtec Announces Expansion of 3-D Tomosynthesis Technology
News | Digital Radiography (DR) | October 04, 2017
October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA
The Siemens Acuson

The Siemens Acuson

Feature | Breast Imaging | October 04, 2017 | By Melinda Taschetta-Millane
According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent...
Overlay Init